The proposed sst 1 pharmacophore (J. Med. Chem. 2005, 48, 523-533) derived from the NMR structures of a family of mono-and dicyclic undecamers was used to design octa-, hepta-, and hexamers with high affinity and selectivity for the somatostatin sst 1 receptor. These compounds were tested for their in vitro binding properties to all five somatostatin (SRIF) receptors using receptor autoradiography; those with high SRIF receptor subtype 1 (sst 1 ) affinity and selectivity were shown to be agonists when tested functionally in a luciferase reporter gene assay. 
I-25) and specifically labeled sst 1 -expressing cells and tissues. 3D NMR structures were calculated for des-AA 1, [4] [5] [6] 10, 12, 13 -[DPhe ]-SRIF-Thr-NH 2 (23) , and des-AA Introduction Somatostatin (SRIF a ) is a cyclic tetradecapeptide widely distributed throughout the body with important regulatory effects (mostly inhibitory) on a variety of endocrine and exocrine functions. It was originally isolated from the hypothalamus and characterized in 1973. 2, 3 Somatostatin is also found in the gut, pancreas, in the nervous system, and in various exocrine and endocrine glands. Somatostatin inhibits the release of growth hormone from the anterior pituitary, insulin and glucagon from the pancreas, and gastrin from the gastrointestinal tract. It also has antiproliferative activity and acts as a neurotransmitter or neuromodulator in the brain. 4-7a SRIF interacts with five specific receptor subtypes (sst 1 -sst 5 ) that have been cloned and characterized, all belonging to the G-protein-coupled receptor family. [8] [9] [10] Cell lines recombinantly expressing these cloned receptors are available to test SRIF analogues for binding affinity, selectivity, and functional effects. 7, [11] [12] [13] So far, only sst 2 and sst 5 receptors have been clearly linked to specific physiological functions. 14, 15 For sst 1 receptors, however, the cellular localization as well as the distinct functions are still not fully understood, similarly to our current lack of knowledge of sst 3 or sst 4 receptor function and physiology.
Sst 1 receptors have been found in human cerebral cortex, 16 human retina, 17 neuroendocrine cells, 14 endothelial cells of human blood vessels (arteries and veins), 18 and human tumors. [19] [20] [21] [22] [23] [24] According to Lanneau 25 and Olias, 14 sst 1 receptors are involved in the intrahypothalamic regulation of growth hormone (GH) secretion. The studies of Kreienkamp et al. suggested an important role for sst 1 in the control of basal GH release in somatotrophs. 26 Zatelli et al. have demonstrated that sst 1 -selective activation inhibits hormone secretion and cell viability in GH-and prolactin-secreting adenomas in vitro and suggested that somatostatin analogues with affinity for sst 1 receptors may be useful to control hormone hypersecretion and reduce neoplastic growth of pituitary adenomas. 27 Sst 1 receptor activation also modulates somatostatin release in basal ganglia. 28 In hypothalamic, basal ganglia, and retinal functions, the sst 1 receptor appears to act as an inhibitory autoreceptor located on somatostatin neurons, whereas in the hippocampus, such a role is still based on circumstantial evidence. Sst 1 -selective analogues could possibly play a role in various diseases. For instance, retinal disease therapeutics has been a suggested indication for sst 1 . 17, [28] [29] [30] Recently, an sst 1 antagonist was shown to promote social interactions, reduce aggressive behavior, and stimulate learning. 31, 32 Matrone et al. demonstrated the role of sst 1 -selective analogues in mediating the inhibitory effect of SRIF on growth hormone secreting pituitary tumors. They suggested that the sst 1 -selective analogues might represent a further useful approach for the treatment of acromegaly in patients resistant or partially responsive to octreotide-LAR or lanreotide treatment in vivo. 33 It has also been reported that in medullary thyroid carcinoma, calcitonin secretion and gene expression can be reduced by treatment with sst 1 -selective agonists by the reduction of cAMP response element binding phosphorylation, suggesting that potent sst 1 -selective agonists could have a therapeutic role in medullary thyroid carcinoma. 34, 35 Furthermore, because sst 1 -selective agonists were able to inhibit endothelial activities, a potential therapeutic utility for administration of sst 1 -selective agonists in the proliferative diseases involving angiogenesis has been suggested. 18 Although numerous reports on the localization, physiological, and therapeutic functions of sst 1 receptors have been published, it is still not clear which is the main sst 1 receptor function and the main sst 1 related pathology. The design of more potent and more (>100-fold) sst 1 -selective agonists and antagonists with radio-labelable properties for in vitro binding assays and in vivo scintigraphy studies as well as greater metabolic stability in biological fluids than the native hormone could help to further understand sst 1 -related biology and pathobiology.
Originally, we had identified the first generation of a peptidic scaffold with selected amino acids (AA) deletions (des-AA 1,2,5 -SRIF) that in combination with DTrp at position 8 and 4-(N-isopropyl)-aminomethylphenylalanine (IAmp) at position 9 yielded des-AA 1,2,5 -[DTrp 8 ,IAmp 9 ]-SRIF (CH-275) 36 (2) ( Table 1 ), a SRIF agonist that was 30-fold more selective for sst 1 versus sst 2/4/5 and 10-fold versus sst 3 , respectively. 36 Our standard drug design approaches led to additional very potent sst 1 ]-SRIF (7) 39 Table 1 . 1, [37] [38] [39] [40] In several drug design studies of different hypothalamic releasing hormones (gonadotropin-releasing hormone (GnRH), 41 corticotropin-releasing factor (CRF), 42 (SRIF 37, 43, 44 ), we had demonstrated that substitutions of natural amino acids with betidamino acids were compatible with biological activity. Betidamino acids are monoacylated derivatives of R-aminoglycine. The synthesis of R-Fmoc, -Boc-aminoglycine was originally described by Qasmi et al., 45 and the synthesis of the methylated derivatives was published by our group. 46 As we demonstrated earlier, the substitution of DTrp 8 by DAgl(NMe,2naphthoyl) 8 in the undecamer scaffold 37 (3 versus 7, Table 1 ) had resulted in a 5-fold increase in binding affinity at sst 1 . 39 Here, we describe the rational design and optimization of a novel class of peptidic somatostatin sst 1 -selective analogues derived from the use of our published sst 1 -pharmacophore model.
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Results and Discussion
Peptide Synthesis. All analogues shown in Table 1 were synthesized either manually or automatically on a 4-methylbenzhydrylamine (MBHA) or chloromethylated (CM) resin using the Boc-strategy and N,N′-diisopropylcarbodiimide (DIC)/ 1-hydroxybenzotriazole (HOBt) for amide bond formation.
We used an unresolved aminoglycine (Agl) derivative Fmoc-D/LAgl(NMe,Boc)-OH 46,47 as a template for the introduction of a betidamino acid in the scaffolds (des-AA 1, [4] [5] [6] 10, 12, 13 -SRIF-Thr/Nal-NH 2 , des-AA 1,2,4-6,10,12,13 -SRIF-Thr/Nal-NH 2 , and des-AA 1,2,4-6,10,12,13 -SRIF-NH 2 ), which resulted in diastereomeric mixtures that were separated by RP-HPLC [48] [49] [50] and were fully characterized. The absolute configuration of the Agl residue in the diastereomers was deduced from enzymatic hydrolysis studies with aminopeptidase M and proteinase K, respectively. Comparison of the enzymatic cleavage patterns of the diastereomers showed that the LAgl-containing analogue was hydrolyzed while the DAgl-containing analogue was not. 50 The peptide resins were treated with anhydrous hydrogen fluoride in the presence of scavengers (anisole and dimethylsulfide) to liberate the fully deblocked crude peptides. Cyclization of the cysteines was mediated by iodine in an acidic milieu. Purification was achieved using multiple RP-HPLC steps. 49 Analytical RP-HPLC, 49 capillary zone electrophoresis (CZE), 51 and mass spectrometry were used to determine the purity and identity of the analogues. NMR Studies. The NMR samples of 16, 23, and 27 were prepared by dissolving 2.5 mg of the peptide in 500 µL of DMSO-d 6 . Assignment of the various proton resonances was carried out using the standard procedure using DQF-COSY, TOCSY, and NOESY experiments. Though 16 showed a single set of resonances for all the protons, two sets of resonances were observed for most of the protons for 23 and 27 in the ratio 60:40, except for the HN and RH resonances of IAmp . This is due to the cis/trans isomerization of the amide bond present in the side chain of the betidamino acid DAgl at position 8 of 23 and 27, as reported earlier. 52 Almost complete assignment of the chemical shifts of the various proton resonances is carried out for 16, 23, and 27 and is shown in parts A-C of Table 2 . Amide resonances of Cys 3 were not observed for 23 and 27 in the NMR spectra due to fast exchange with the solvent.
A reasonably large number of experimental NOEs is observed for the three analogues in the NOESY spectrum measured with a mixing time of 100 ms, leading to over 70 meaningful distance restraints per analogue (Table 3, Figure 1 ). For all analogues, structural restraints from NOEs were used as input for the structure calculation with the program CYANA, 53 followed by restrained energy minimization using the program DIS-COVER. 54 The resulting bundle of 20 conformers per analogue represents the 3D structure of each analogue. For each analogue, the small residual violations in the distance constraints only for the 20 refined conformers (Table 3 ) and the coincidence of experimental NOEs and short interatomic distances (data not shown) indicate that the input data represent a self-consistent set and that the restraints are well satisfied in the calculated conformers (Table 3 ). The deviations from ideal geometry are minimal, and similar energy values were obtained for all 20 conformers of each analogue. The quality of the structures determined is reflected by the small backbone rmsd values relative to the mean coordinates of ∼0.5 Å (see Table 3 and Figure 2 ). Figure 2A , Table 4 ). In all of the calculated 20 conformers, there is a hydrogen bond between the amide protons of Phe 11 to the carbonyls of Phe 8 and the deletion of DPhe 2 at the N-teminus (Table 1) . With those modifications, 23 binds selectively to sst 1 with high affinity (IC 50 ) 1 nM). The 3D NMR structure of 23 shows that the angles around DAgl(NMe,2naphthoyl) 8 and IAmp 9 do not represent any standard -turns ( Figure 2B , Table 4 ). The side chains of Phe (Table 4 ). In addition, the side chains of Phe 7 and DAgl(NMe,2naphthoyl) 8 span a large conformational space ( Figure 2B , Table 4 ). In the major conformer, the side chain methyl protons of DAgl(NMe,2naphthoyl) 8 give rise to NOE/ ROEs to both the H1 and H8 protons of the naphthoyl group, suggesting that DAgl(NMe,2naphthoyl) 8 is in trans isomer in the major conformer. On the basis of the large number of NOEs (27) . The composition of 27 is different from that of 23, with Tyr 11 replacing Phe 11 and the deletion of Thr 15 at the C-terminus (Table 1 ), yet it binds selectively to sst 1 with high affinity (IC 50 ) 6 nM). The 3D NMR structure shows that the angles around DAgl(NMe,2naphthoyl) 8 and IAmp 9 do not represent any standard -turns ( Figure 2C , Table 4 ). The side chains of Phe 7 and Tyr 11 are in the gauche + configuration, and the side chains of DAgl(NMe,2naphthoyl) 8 and IAmp 9 are in the gauche -configuration ( Table  4) . The side chains of DAgl(NMe,2naphthoyl) 8 and IAmp 9 span a large conformational space ( Figure 2C , Table 4 ). In the major conformer, the side chain methyl protons of DAgl(NMe,2naphthoyl) 8 give rise to NOE/ROEs to both the H1 and H8 protons of the naphthoyl group, suggesting that DAgl(NMe,2naphthoyl) 8 is in trans isomer in the major conformer. On the basis of the large number of NOEs observed, the 3D NMR structure of the major conformer was calculated and this is assumed to be the bioactive conformation. Moreover, the minor conformer was poorly defined due to the few number of NOEs that could be identified for this conformation.
Biological Testing. To determine their SRIF receptor-binding properties, the compounds were tested for their ability to bind to cryostat sections of a membrane pellet of cells expressing the five human SRIF receptor subtypes ( 55 The results are shown in Table 1 . The most potent and selective analogues were functionally evaluated for their agonist/antagonist properties using a reporter gene assay that determines the biological activity of the human sst 1 receptor in CCL39-sst 1 -Luci cells, constitutively expressing the human sst 1 receptor as well as the luciferase gene under the control of the serum response element (SRE). The SRE is regulated by transcription factors and is activated by many extracellular signals including ligands acting at G-protein-coupled receptors. 56, 57 It has been shown that upon 43 a shortsized somatostatin analogue with no affinity to sst 1 receptor used as a negative control, was unable to stimulate luciferase gene expression in CCL39-sst 1 -Luci cells. The results of the reporter gene assay are summarized in Table 1 .
Structure-Activity Relationship Studies. The proposed sst 1 receptor pharmacophore 1 derived from the NMR structures of the family of the undecamers (mono and dicyclic) 37 ,38 compared with the previously proposed sst 2 , sst 2, 5 , and sst 4 pharmacophores are shown in Figure 4 .
With a well-defined pharmacophore, we were now in a position to design improved analogues following a rational approach. In this regard, we designed putative sst 1 -selective octa-, hepta-, and hexamers derived from the known undecamers.
1 Figure 4A shows that the sst 1 -selective agonist-pharmacophore has two aromatic side chains, at position 6 or 7 and 11, in addition to the DTrp 8 and IAmp 9 pair. The sst 1 selectivity is achieved mainly through the amino acid IAmp at position 9, which replaces Lys, present in most of the somatostatin analogues. The side chain of IAmp is longer than the side chain of Lys, it has an aromatic group (amino-methylphenylalanine) extended by a relatively bulky aliphatic group (isopropyl). Hence, we conclude that IAmp cannot be accommodated in a smaller binding pocket that will fit a smaller side chain as that of Lys 9 critical for sst [2] [3] [4] [5] binding. We propose that only in the sst 1 receptor structure is the binding pocket large enough to accommodate the side chain of IAmp (comparing the residues in the models of the transmembrane regions of the somatostatin receptors based on the crystal structure of rhodopsin) and therefore analogues with IAmp at position 9 show selectivity for sst 1 .
We wanted to identify smaller peptidic molecules than the undecamers, which would retain selectivity as well as good affinity at sst 1 receptors and possibly would act as antagonists having greater metabolic stability than the previously published analogues. [36] [37] [38] [39] 59 As we published earlier, the hypothesis that IAmp 9 by itself might establish sst 1 selectivity in the otherwise potent pan-somatostatin octapeptide des-AA ]-SRIF (9), which showed no binding affinity to any SRIF receptor, 37 most probably due to steric effects perturbing the alignment of the DTrp 8 -IAmp 9 side chains with respect to the other aromatic side chains.
Because the backbone conformations of the sst 1 -selective analogues have a hairpin-like structure similar to that of the sst 2/3/5 -selective octreotide-based analogues, we decided to introduce IAmp at position 9 in the octreotide scaffold with the additional substitutions (an aromatic side chain at positions 6 or 7 and at position 11) indispensable to fulfill the sst 1 pharmacophore's requirements (see below).
With the aim of searching for sst 1 based analogues, they do not have Phe at position 11. Hence, we replaced Thr at position 10 by Phe at 11 (as in SRIF), leaving four residues and the two Cys residues in the cycle. This analogue (16) exhibited similar affinity to sst 1 (IC 50 ) ∼30 nM) as 8, but it is more selective because it shows low affinity to the other four receptors (see Table 1 ). Therefore analogue 16 was selected as lead for further derivatization. Our SAR studies focused on positions 2, 3, 8, 9, 11, and 15 of the analogue 16 (SRIF numbering). Affinities to the five SRIF receptors were determined in receptor binding assay and are summarized in Table 1. SAR at position 2 where DPhe, Cpa, Tyr, and DTyr were substituted show that these residues can be eliminated with only small differences in binding affinity to sst 1 (des-AA ]-SRIF-2Nal-NH 2 (31)). We suggest that the individual nature of these amino acids (despite the fact that their side chains are not involved in binding) is responsible for the differences in affinity. SAR at position 3 suggests that the substitution of Cys with DCys has little effect on sst 1 binding affinity and function. SAR at position 8 shows the unique nature of Agl 8 -containing analogues that are all highly selective for sst 1 over the other four receptor subtypes (23, 25, 27, 29) . Interestingly, for this scaffold, a D-configuration is significantly more favorable than the Lconformation. SAR at position 9 shows that the introduction of IAmp results in more active and selective analogues (des-AA (27) . This peptide selectively binds to sst 1 with an average IC 50 ) 6.0 nM, (IC 50 >1000 nM at sst 2 , 317 nM at sst 3 , 481 nM at sst 4 , and >1000 nM at sst 5 , respectively). Compared to our previously published analogues, which contained 11 residues, 27, containing only 6 residues, is a much smaller and appealing molecule.
Although des-AA 50 for sst 1 ) 27 nM), and 5 (IC 50 for sst 1 ) 2.5 nM). 1 The lower affinities of these analogues could be explained based on the knowledge of the sst 1 pharmacophore and be due to one or more of the following reasons: (1) the distances between the side chains of the residues involved in binding may be slightly different from the distances required by the sst 1 Figure 4A) 1 ) that the side chains possibly occupy the binding pocket partially, (2) the conformational rigidity in the side chain of DTrp at position 8 is in such a way that it cannot occupy completely the available binding pocket, (3) although the analogues have two aromatic residues, the aromatic side chains could be on the front side of the peptide backbone (when displayed from N to the C-terminus), resulting in µM binding affinity.
In the octreotide pharmacophore, the side chains of DTrp 8 and Lys 9 are in close proximity (4-6 Å), 62, 63 ( Figure 4C ), whereas in the sst 1 -pharmacophore, the side chains of DTrp 8 and IAmp 9 are farther apart (7-8 Å) ( Figure 4A ). Because the side chain of aminoglycine (Agl) has been shown to span a larger volume than the DTrp side chain, we introduced acylated Agl at position 8. 52 This substitution in the shortened analogues (21, 23, 25, 27, 29, and 31) improved the binding affinity and selectivity for sst 1 as well. Some of these analogues also exhibit binding to sst 4 sst 2/5 , 500-fold selectivity versus sst 3 , and 100-fold selectivity versus sst 4 , respectively. SRIF and the sst 1 -agonist 33 exhibit EC 50 values of 0.93 and 33 nM, respectively. Figure 3 shows that SRIF, 25 and 33 are agonists because they effectively stimulate luciferase expression in the reporter gene assay. It is noteworthy to mention that 25 is more potent than SRIF (EC 50 : 0.37 nM versus EC 50 : 0.93 nM), whereas the standard sst 1 agonist 33 is approximately 100-fold less potent than either of them. We have used 35, 3,4 a short-sized somatostatin analogue with no affinity to sst 1 receptors, as a negative control, in this test; it was found to be inactive at a concentration of 1 µM.
Analogue 25 was radio-iodinated with 125 I and found to bind to sections of membrane pellet of sst 1 -expressing transfected cells with high specificity, as shown in Figure 5 . Moreover, we evaluated the ability of the 125 I-25 to bind to sst 1 -expressing human cancers. Table 6 shows that this radioligand was able to label virtually all tested sst 1 -expressing tumors, including a selection of well characterized sst 1 -expressing prostate cancers, mesenchymal cancers, bronchial carcinoids, and gastroenteropancreatic tumors. Figure 6 and Table 6 show that compared to the strong 125 I-[LTT]-SRIF-28 labeling, found to be fully displaceable by 33 in these tissues and therefore indicative of sst 1 (Table 6 ) despite an extremely high density of sst 2 receptors in these tumors. This further indicates the high sst 1 specificity of the tracer.
The sst 1 pharmacophore reported previously by our group showed that the side chains of four different residues are important for the binding of these analogues. 1 They are the indole ring of DTrp at position 8, IAmp side chain at position 9, and two aromatic side chains at positions 6 or 7 and 11. The distances between the side chains of these residues should be close to the values given in Table 5 . 1 In addition, the sst 1 pharmacophore was different from the other SRIF receptor pharmacophores 63, 66, 67 in the positioning of the aromatic side chains. In all of the other SRIF receptor pharmacophores, the aromatic side chains are present at the front side of the peptide backbone when the structure of the peptide is oriented from Nto C-terminus. In contrast, in the sst 1 pharmacophore, both of the aromatic side chains are present at the back side of the peptide backbone.
1 Therefore, any peptide that has the sst 1 pharmacophore that involves the four residues at the proposed distance should bind to sst 1 .
To verify the identity of the sst 1 pharmacophore, the 3D structures of three analogues, 16, 23, and 27, that bind selectively to sst 1 with nM affinity were studied. All these analogues have IAmp at position 9, which is crucial for selectivity to sst 1 . As shown in Figure 2 , the other residues important for sst 1 , are present in all of the three analogues. The distances between the corresponding Cγ atoms of the side chains of the four residues are given in Table 5 . Comparing the distances with the sst 1 pharmacophore suggests that all of the three analogues have the sst 1 pharmacophore, except for a small discrepancy, but a detailed comparison of the structures show that the positioning of the side chains of the aromatic groups at position 7 and 11 is not exactly identical to that described for the sst 1 pharmacophore. 1 In the structures of the three analogues studied here, the aromatic side chains are present in the front side of the peptide backbone (Figure 2 ). Because these peptides have high binding affinity for sst 1 , the binding of these peptides to sst 1 could be due to the inherent flexibility observed in these peptides. The presence of DAgl at position 8 introduces a large flexibility to the peptide backbone and in turn to the side chains of 23 and 27, compared to 16, which has DTrp at position 8. This is also reflected in the number of NOEs observed for 23 and 27, which is less compared to the number of NOEs observed for 16 (Table 3 ). In addition, the chemical shift values observed for the aromatic protons of Phe 7 and Phe 11 are very similar for 23 and 27 (parts B and C of Table 2 ), indicating a random coil or less structured elements compared to 16 (part A of Table 2 ). Comparing the chemical shift dispersion of the aromatic region of similar sst 2 -selective octreotide-type SRIF analogues 63 with these sst 1 - selective analogues suggests that the latter are less structured in DMSO (Figure 7) . On the basis of the conformational flexibility of 23 and 27 (parts B and C of Table 2 , it is suggested that the aromatic side chains could move to the backside of the peptide backbone for sst 1 binding. The higher binding affinity of 23 and 27 compared to that of 16 could be due to the larger flexibility of the peptide backbone of the former, resulting in a better fit of 23 and 27 into the sst 1 binding pocket compared to 16, which shows a single conformation with much less flexibility for its peptide backbone (parts A-D of Figure 2 , Table 5 ).
Conclusions
To conclude, using a pharmacophore derived from the structures of undecamers, 1 we were able to design somatostatin heptamers and hexamers with improved or similar affinity and sst 1 selectivity compared to the previously published undecamers. Although the positioning of the aromatic side chains in these shortened analogues is not exactly identical to that found for the sst 1 pharmacophore proposed earlier, backbone flexibility is suggested as a mechanism for induced fit necessary for sst 1 binding.
These results demonstrate that rational and efficient SAR in peptides is possible. In this case, it was critical that the structure of the original pharmacophore be well-defined and accurate.
This was the case because it was based on the structures of several high affinity ligands of differing primary sequences. 1 The most potent of these sst 1 -selective analogues (25) in respect of affinity, selectivity, and functionality could be radio-iodinated. While this tracer is highly specific for labeling sst 1 -expressing tumors with very high binding affinity, the sensitivity of the assay using this radioligand remains below expectations. This is somewhat disappointing, but it should be kept in mind that agonist radioligands are not devoid of caveats. We have shown previously that although octreotide in receptor autoradiography when using slices of brain or peripheral tissues known to express SRIF receptors, 70 illustrating the fact that all agonists are not equal.
Experimental Procedures
Chemistry: Starting Materials. The Boc-Cys(Mob)-CM resin with a capacity of 0.3-0.5 mequiv/g was obtained according to published procedures. 71 All N R -tert-butoxycarbonyl (BOC) protected amino acids with side chain protection were purchased from Bachem Inc. 72 Fmoc-D/LAgl(ΝMe,Boc), 46 and Fmoc-DAgl(Boc) 73 were synthesized in our laboratory. All reagents and solvents were reagent grade or better and used without further purification.
Peptide Synthesis. Peptides were synthesized by the solid-phase approach with Boc chemistry either manually or on a CS-Bio peptide synthesizer model CS536. Boc-Cys(Mob)-CM resin with a capacity of 0.3-0.5 mequiv/g or 4-methylbenzhydrylamine (MBHA) resin with a capacity of 0.4 mequiv/g was used, respectively. Couplings of the protected amino acids were mediated by diisopropylcarbodiimide (DIC) and (HOBt) in DMF for 1 h and monitored by the qualitative ninhydrin test. 74 A 3 equiv excess of the protected amino acids based on the original substitution of the resin was used in most cases. Boc removal was achieved with trifluoroacetic acid (60% in CH 2 Cl 2 , 1-2% ethanedithiol or m-cresol) for 20 min. An isopropyl alcohol (1% m-cresol) wash followed TFA treatment, and then successive washes with triethylamine solution (10% in CH 2 Cl 2 ), methanol, triethylamine solution, methanol, and CH 2 Cl 2 completed the neutralization sequence. D/LAgl(NMe,2naphthoyl) residue was formed on the resin. In short: after Fmoc-D/LAgl(ΝMe,Boc)-OH was coupled, the Boc protecting group was removed with TFA, 3 equiv 2naphthoyl chloride, and 3 equiv DIPEA were used to acylate the free secondary amino group of the side chain. Removal of the Ν R -Fmoc protecting group with 20% piperidine in DMF in two successive 5 and 15 min treatments was followed by the standard elongation protocol until the completion of the peptide.
All of the peptides were cleaved from the resin support with simultaneous side chain deprotection by anhydrous HF containing the scavengers anisole (10% v/v) and methyl sulfide (5% v/v) for 60 min at 0°C. The diethyl ether precipitated crude peptides were cyclized in 75% acetic acid (200 mL) by addition of iodine (10% solution in methanol) until the appearance of a stable orange color. Forty minutes later, ascorbic acid was added to quench the excess iodine.
Purification and Characterization of the Analogues. The crude, lyophilized peptides were purified by preparative RP-HPLC 49 on a 5 cm × 30 cm cartridge, packed in the laboratory with reversed-phase Vydac C 18 silica (15-20 µM particle size, 300 Å) using a Waters Prep LC 4000 preparative chromatograph system with a Waters 486 tunable absorbance UV detector and Huston Instruments Omni Scribe chart recorder. The peptides eluted with a flow rate of 100 mL/min using a linear gradient of 1% B per 3 min increase from the baseline % B. Eluent A ) 0.25 N TEAP pH 2.25, eluent B ) 60% CH 3 CN, 40% A. As a final step, all peptides were rechromatographed in a 0.1% TFA solution and CH 3 CN on the same cartridge at 100 mL/min (gradient of 1% CH 3 CN/min). The collected fractions were screened by analytical RP-HPLC on a system using two Waters 501 HPLC pumps, a Schimadzu SPD-6A UV detector, a Rheodyne model 7125 injector, a Huston Instruments Omni Scribe chart recorder, and a Vydac C 18 column (0.46 cm × 25 cm, 5 µm particle size, 300 Å pore size). The fractions containing the product were pooled and subjected to lyophilization. The purity of the final peptide was determined by analytical RP-HPLC performed with a linear gradient using 0.1 M TEAP pH 2.5 as eluent A and 60% CH 3 CN/40% A as eluent B on a Hewlett-Packard series II 1090 liquid chromatograph connected to a Vydac C 18 column (0.21 cm × 15 cm, 5 µm particle size, 300 Å pore size). The capillary zone electrophoresis (CZE) analysis of the peptides was performed on a Beckman P/ACE System 2050; field strength of 15 kV at 30°C on an Agilent µSil bare fusedsilica capillary (75 µm id × 40 cm length). 51 Mass spectra (MALDI-TOF-MS) were measured on an ABI-Perseptive DE-STR instrument. The instrument employs a nitrogen laser (337 nm) at a repetition rate of 20 Hz. The applied accelerating voltage was 20 kV. Spectra were recorded in delayed extraction mode (300 ns delay). All spectra were recorded in the positive reflector mode. Spectra were sums of 100 laser shots. Matrix R-cyano-4-hydroxycinnamic acid was prepared as saturated solutions in 0.3% TFA in 50% CH 3 ]-SRIF2Nal-NH 2 (32)) were not resolved initially, two diastereomers were generated, isolated, characterized, and tested. Separation of the Lfrom the DAgl-containing peptides was achieved using RP-HPLC. The absolute configuration of the Agl was deduced from enzymatic hydrolysis studies with trypsin, aminopeptidase M, and proteinase K (Roche Diagnostics Corp., Indianapolis, IN), respectively, as we published earlier. 50 All enzymatic hydrolyses were carried out according to the protocols suggested by the manufacturers.
Trypsin, which is highly specific toward positively charged side chains with lysine and arginine, was used to determine the stereochemistry of 21 and 22. Trypsin (Roche, 5 µg) in 0.05% TFA (20 µL) was added to peptide (0.02 µmol) dissolved in 0.046 M Tris buffer (200 µL, pH ) 8.1) containing 0.01 M CaCl 2 . The hydrolysis was followed by RP-HPLC for 6 days. Trypsin was able to open the ring structure of 21 and 22, but the rate of reactions was very much different. We suggest that 22 contains the L-isomer of the Agl derivative and 21 contains the D-isomer of the Agl derivative because 55% of 22 versus only 28% of 21 were hydrolyzed in 6 days.
Peptides with L-amino acids at their N-terminus and IAmp at position 9 instead of Lys (23 versus 24 and 27 versus 28) were digested with aminopeptidase M, which is a metalloprotease, and can hydrolyze peptides at a free R-amino group of L-amino acids (except X-Pro bonds and the amino groups of Asp, Gln, or Ala) to determine the absolute configuration of Agl. The treatment of 24 and 28 with aminopeptidase M at room temperature for 48 h resulted in many very hydrophilic products followed by RP-HPLC, indicating that these peptides have been completely hydrolyzed, providing evidence that these analogues contained the L-enantiomer of Agl in their sequence. Compounds 23 and 27 were hydrolyzed only into two products, suggesting that these two peptides contained the D-enantiomer of Agl in their sequence, resulting in more resistance to the enzymatic hydrolysis. To confirm this conclusion, these analogues were also digested with proteinase K, which is a serine protease that exhibits very broad cleavage specificity. The predominant site of cleavage is the peptide bond adjacent to the carboxyl group of hydrophobic aliphatic and aromatic amino acids with blocked R amino groups. Peptides were dissolved (20 µg) at a concentration of 0.3 mg/mL in 10 mM Tris buffer pH 7.8. Proteinase K (5 µL, 6 U) was added and reacted for 16 h at 37°C. An aliquot (5 µL) was quenched with 45 µL 0.1 N HCl prior to analysis by HPLC for determination of degradation products. The aliquots were screened using microbore RP-HPLC under buffer system A; 0.1%TFA/H 2 O, buffer system B, 70% CH 3 CN in A at a flow rate of 0.05 mL/min under gradient conditions 10-80% B over 30 min. Fragments of 23 identified as H-Phe-Agl(NMe,-2naphthoyl)-IAmp-Phe-Cys-Thr-NH 2 andH-Phe-Agl(NMe,2naphthoyl)-IAmp-Phe-OH were confirmed by MALDI-MS. These observations verified that 23 contained the DAgl. The mass of fragments of 24 were found to be <500 Da, indicating the presence of LAgl.
Analogues 25, 26, 29, 30, and 31 and 32 contain a D-residue at position 2 (DTyr) or 3 (DCys), respectively, therefore enzymatic hydrolysis by aminopeptidase M could not be expected for any of these compounds. Instead, these analogues were digested with proteinase K as described above.
The digestion of 25 with proteinase K for 4 days resulted in four products, which were identified as H-cyclo The digestion of 31 with proteinase K for 47 h resulted in three fragments, which were identified as H-cyclo[DCys-PheAgl(NMe,2naphthoyl)-IAmp-Phe-Cys]-Nal-NH 2 , H-DCys-(CysNal-NH 2 )-Phe-Agl(NMe,2naphthoyl)-IAmp-Phe-OH, and H-DCysPhe-Agl(NMe,2naphthoyl)-IAmp-Phe-OH and the starting material confirmed by MALDI-MS. After the digestion of 32 with proteinase K for 47 h, a small amount of the starting material was detected by HPLC and no other fragments could be identified, suggesting that this peptide contains the L-isomer of Agl.
Overall, aminoglycine-containing enantiomers were relatively easy to separate using HPLC under gradient conditions (Table 7) . NMR Experiments. The 1 H NMR spectra were recorded on a Bruker 700 MHz spectrometer operating at proton frequency of 700 MHz. Chemical shifts were measured using DMSO (δ ) 2.49 ppm) as an internal standard. The 2D spectra were acquired at 298 K. Resonance assignments of the various proton resonances have been carried out using total correlation spectroscopy (TOCSY), 75, 76 double-quantum filtered spectroscopy (DQF-COSY), 77 and nuclear Overhauser enhancement spectroscopy (NOESY). [78] [79] [80] The TOCSY experiments employed the MLEV-17 spin-locking sequence suggested by Davis and Bax, 75 applied for a mixing time of 50 or 70 ms. The NOESY experiments were carried out with a mixing time of 100 or 150 ms. The TOCSY and NOESY spectra were acquired using 800 complex data points in the ω 1 dimension and 1024 complex data points in the ω 2 dimension and were subsequently zero-filled to 1024 × 2048 before Fourier transformation. The DQF-COSY spectra were acquired with 1024 × 4096 data points and were zero-filled to 2048 × 4096 before Fourier transformation. The TOCSY, DQF-COSY, and NOESY spectra were acquired with 16, 16, and 24 scans, respectively, with a relaxation delay of 1 s. The signal from the residual water of the solvent was suppressed using presaturation during the relaxation delay and during the mixing time. The TOCSY and NOESY data were multiplied by a 75°shifted sine-function in both dimensions. To differentiate exchange peaks from the NOEs, rotating frame NOESY (ROESY) 81, 82 spectra were measured at 150, 250, and 400 ms. All spectra were processed using the software PROSA. 83 The spectra were analyzed using the software X-EASY. 84 Structure Determination. The chemical shift assignment of the major/minor conformer was obtained by the standard procedure using DQF-COSY and TOCSY spectra for intraresidual assignment and the NOESY spectrum was used for the sequential assignment. 85 The collection of structural restraints is based on the NOEs and vicinal 3 J NHR couplings. Dihedral angle constraints were obtained from the 3 J NHR couplings, which were measured from the 1D 1 H NMR spectra and from the intraresidual and sequential NOEs along with the macro GRIDSEARCH in the program CYANA. 53 The calibration of NOE intensities versus 1 H-1 H distance restraints and appropriate pseudoatom corrections to the nonstereo specifically assigned methylene, methyl, and ring protons were performed using the program CYANA. On an average, approximately 70 NOE constraints and 15 angle constraints were utilized while calculating the conformers (Table 3) . A total of 100 conformers were initially generated by CYANA, and a bundle containing 20 CYANA conformers with the lowest target function values were utilized for further restrained energy minimization using the program DIS-COVER with steepest decent algorithm. 54 The resulting energy minimized bundle of 20 conformers was used as a basis for discussing the solution conformation of the different SRIF analogues. The structures were analyzed using the program MOL-MOL.
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Biology: Reagents. All reagents were of the best grade available and were purchased from common suppliers. Lactalbumin hydrolysate was from HyClone, ATP from Sigma-Aldrich, D-luciferin from Roche Diagnostics, and coenzyme A from Calbiochem.
Cell Lines. Chinese hamster lung fibroblasts (CCL39) stably expressing the human sst 1 and the luciferase reporter gene under the control of the serum response element (CCL39-sst 1 -Luci) were from D. Hoyer (Novartis, Basel, Switzerland) and grown in DMEM with GlutaMAX-I/Ham's F-12 Nut. Mix. with GlutaMAX-I (1:1) supplemented with 10% fetal bovine serum, 100U/mL penicillin, 100 µg/mL streptomycin, and 400 µg/mL geneticin (G418-sulfate) at 37°C and 5% CO 2 . All culture reagents were from Gibco BRL, Life Technologies.
Receptor Autoradiography. Cell membrane pellets were prepared as previously described and stored at -80°C. 87 Receptor autoradiography was performed on 20 µm thick cryostat (Microm HM 500, Walldorf, Germany) sections of the membrane pellets, mounted on microscope slides, and then stored at -20°C. 2), the sections were dried quickly and exposed for 1 week to Kodak BioMax MR film. IC 50 values were calculated after quantification of the data using a computer-assisted image processing system as described previously. 88 Tissue standards (Autoradiographic [
125 I] and/or [ 14 C] microscales, GE Healthcare, Little Chalfont, UK) that contain known amounts of isotope, crosscalibrated to tissue-equivalent ligand concentrations, were used for quantification. [88] [89] [90] [91] The analogue 25 was 125 I-monoradiolabeled (2000 Ci/mmol, ANAWA, Switzerland) and used as radioligand in binding studies on cell membrane pellet sections of cells stably expressing sst 1 receptors and on tissue sections, following the same protocol as described above for 125 I-[LTT]-SRIF-28. Luciferase Assay. The luciferase reporter gene assay was performed as described previously by Hoyer and colleagues 32, 58 with minor modifications. CCL39-sst 1 -Luci cells were seeded at 25000 cells per well in 96-well plates. After 24 h, the cells were washed once with PBS and then serum-deprived for 24 h in assay medium (DMEM with GlutaMax-I/Ham's F12 Nut. Mix. with GlutaMax-I (1:1) containing 5 g/L lactalbumin hydrolysate and 20 mM HEPES) at 37°C and 5% CO 2 . The cells were then treated in triplicate at 37°C and 5% CO 2 with assay medium alone (basal) or with assay medium containing the compounds to be tested at concentrations between 0.1 nM and 1 µM for 5 h. The cells were then washed with PBS and lysed in lysis buffer (100 mM KPibuffer containing 0.2% Triton X-100 and 1 mM DL-dithiothreitol). Luciferase activity was measured using a luminometer by injecting first the ATP reagent (10 mM ATP, 35 mM glycyl-glycine, and 20 mM MgCl 2 , pH 7.8) and then the luciferin reagent (0.47 mM D-luciferin, 0.27 mM coenzyme A, 35 mM glycyl-glycine, and 20 mM MgCl 2 , pH 7.8). Measuring parameters: delay time, 5 s; measurement time, 10 s. The 1 µM SRIF-14 effect minus the basal effect was set as 100%. Stimulation of luciferase reporter gene activity by the different compounds is expressed as % stimulation of the 1 µM SRIF-14 effect. As positive control for the luciferase reporter gene activity, 10% fetal bovine serum in assay medium was used.
